Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the importance of understanding how efficacy and safety data from clinical trials translate to the real world, and describes that recently published real-world outcomes mirror what was shown in pivotal clinical trials, supporting real-world use of lisocabtagene maraleucel.